Archived explainer. For the current picture see today's NVS page.
Why Is NOVARTIS AG ADR (NVS) Stock Down Today?
By the Top Tier Newswire AI Desk · September 8, 2026 at 9:50 AM ET · reviewed against 41 wire stories
NOVARTIS AG ADR (NVS) is down -12.83% in the latest session. Our newswire has captured 41 stories on NVS across 19 sources in the last 36 hours, with AI sentiment reading bearish (avg 38/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Why NVS stock is down today
Novartis AG ADR (NVS) fell 12.83% to $139.47 in the session, marking one of its worst performances in recent memory. The decline followed the announcement that its Phase 3 HARBOR study for del-Desiran in treating myotonic dystrophy type 1 did not meet its primary endpoint. This is the second major drug development setback for the company in a short span, raising concerns about its pipeline and future growth.
What Happened
The stock opened at $140.43, a -12.2% gap down from the previous close of $159.99. It quickly declined further, hitting a session low of $138.85. The HARBOR study failure comes just days after another setback, compounding investor concerns. The Fly and Barron's highlighted the negative implications, with the latter noting that more pain could follow for Novartis in the near term. The failure also raised broader questions for biotech partners, as reported by Benzinga. Jefferies noted that Dyne Therapeutics could gain attention as a potential alternative in the myotonic dystrophy space.
What The Data Shows
The stock traded at a volume of 1.0 million shares, which is 0.6 times its 3-month average. The session high of $140.66 was reached at 7:00 AM ET, while the low of $138.85 followed at 7:40 AM. Over the past eight sessions, the stock had risen 1.4% from $158.10 to $160.30. On September 8, the stock printed two fresh 52-week highs and two 52-week lows. The 52-week range for the stock is $121.57 to $170.46.
What To Watch
Investors should monitor the broader market reaction to Novartis' setbacks and any further developments in its drug pipeline. No earnings date is provided, but coverage breadth and potential follow-up trials could shape the next steps for the stock.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
Find insight on Klinique Medical Clinic, Novartis, Daiichi Sankyo and more in the latest Market Talks covering Health Care.
5d agoThe FlyBULLISH 67Analyst
Dyne ‘claims frontrunner status in DM1’ after Novartis failure, says Jefferies
5d agoThe FlyBEARISH 32Earnings
Dyne Therapeutics sinks after Novartis myotonic dystrophy miss
5d agoThe FlyBEARISH 34Product/PR
Novartis falls after Phase 3 HARBOR study for DM1 did not meet primary endpoint
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →